2 completed, 1 active not recruiting, 1 terminated. 4 Phase 1.
By phase and status
Follow ABBV-368: new trials by email Literature Review of ABBV-368 trials Research Report on ABBV-368
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
ABBV-181, ABBV-368, ABBV-927 - Head and Neck Cancer | Phase 1 | Terminated | AbbVie | 3 | 2020-01-22 | 2020-12-31 |
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer | Phase 1 | Completed | AbbVie | 30 | 2020-01-22 | 2023-02-27 |
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
ABBV-927, ABBV-368, ABBV-181 - Cancer, Advanced Solid Tumors | Phase 1 | Active not recruiting | AbbVie | 150 | 2019-05-21 | 2026-09-02 |
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
ABBV-368, ABBV-181 - Advanced Solid Tumors Cancer | Phase 1 | Completed | AbbVie | 139 | 2017-03-21 | 2022-04-28 |
Conditions studied
Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Cholangiocarcinoma (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Mesothelioma (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Sponsors
AbbVie (4)
Countries
United States (4) · France (3) · Spain (3) · Israel (2) · Taiwan (2) · Australia (1) · Germany (1) · Japan (1) · Netherlands (1) · Puerto Rico (1)
Results publications
PMID 41956545
NIH funding
2019 (2), 2016 (1)